COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621001081808
Ethics application status
Approved
Date submitted
16/06/2021
Date registered
16/08/2021
Date last updated
16/08/2021
Date data sharing statement initially provided
16/08/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Reward learning and Cognitive Remediation
Scientific title
The effect of cognitive remediation on reward learning in adults with schizophrenia spectrum disorder
Secondary ID [1] 304499 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Schizophrenia spectrum disorder 322349 0
Condition category
Condition code
Mental Health 320026 320026 0 0
Schizophrenia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This pilot examines whether reward learning is the mechanism of effect for people with schizophrenia spectrum disorder receiving a evidence based therapy, cognitive remediation (CR) that aims to improve cognition
What is CR
CR involves a range of cognitive tasks that focus on attention, memory and planning via drill and practice and strategy based interventions
What is involved in participating in CR
The CR program is twice a week for 1 hour of a computer based program
The first session is face to face with subsequent sessions online with remote facilitation via team software
The program is 20 sessions with the time taken to complete 20 sessions usually taking 12 weeks.
CR is delivered by trained CR therapists of a range of disciplines
The program notes progress and sessions completed as well as therapist keeping a record of attendance
Intervention code [1] 320860 0
Behaviour
Intervention code [2] 321359 0
Rehabilitation
Comparator / control treatment
No comparative or control
Control group
Uncontrolled

Outcomes
Primary outcome [1] 327888 0

Change in reward processing as measured via the BIS/BAS

Timepoint [1] 327888 0
baseline( pre intervention) and post completion of 20 session
Primary outcome [2] 328139 0
Changes in reward processing as measured by fMRI task
Timepoint [2] 328139 0
Post completion of CR 20 sessions
Primary outcome [3] 328328 0
Changes in Behavioural Inhibition Scale BIS/Behavioural Activation Scale BAS
Timepoint [3] 328328 0
On assessment after completing 20 sessions
Secondary outcome [1] 396894 0
Changes in working memory post CR intervention as measured by a composite of:
Brief Assessment of Cognition in Schizophrenia (BACS)
Schizophrenia Cognition Rating Scale (SCoRS)
Timepoint [1] 396894 0
Baseline and 12 weeks at the end of therapy
Secondary outcome [2] 397800 0
Changes in negative symptoms as measured by Clinical Assessment Interview for Negative symptoms (CAINS)
Timepoint [2] 397800 0
Baseline and 12 weeks at completion of CR program

Eligibility
Key inclusion criteria
• Patients of the Metro South Addiction and Mental Health Service
• Primary diagnosis of schizophrenia spectrum disorder
• Basic competence in written and spoken English
• Capacity to consent as advised by the treating team
• Aged between 18-35
• No history of neurological disorders or acquired brain injury.
• Estimated intelligence quotient >70
Minimum age
18 Years
Maximum age
35 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• Participants known or have any suspicion that you may have a metallic object in your body. This includes things such as a cardiac pacemaker, cochlear implant, metal IUD (hormonal IUD’s made of plastic are fine), neuro-stimulator, aneurysm clips, non-removable body piercing, history of shrapnel or metal fragments in the eye.
• Are pregnant or possibly pregnant (unprotected sex since last menstrual period).
• History of claustrophobia.
• Have permanent metal braces or a molar retainer.
weigh more than 120kg

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint(s)
Efficacy
Statistical methods / analysis
For the fMRI analysis the General Linear Model approach for event-related designs will be conducted using SPM8 (http://www.fil.ion.ucl.ac.uk).

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 20144 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 34869 0
4102 - Woolloongabba

Funding & Sponsors
Funding source category [1] 308860 0
Hospital
Name [1] 308860 0
Princess Alexandra Hospital and health service
Address [1] 308860 0
199 Ipswich Rd
Woolloongabba
Brisbane 4102
Quuensland
Country [1] 308860 0
Australia
Primary sponsor type
Hospital
Name
Princess Alexandra Hospital and health service
Address
199 Ipswich Rd
Woolloongabba
Brisbane 4102
Queensland
Country
Australia
Secondary sponsor category [1] 309779 0
Other
Name [1] 309779 0
Translational Research Institute
Address [1] 309779 0
37 Kent St
Woolloongabba
Brisbane 4102
Queensland
Country [1] 309779 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 308770 0
Metro South HREC
Ethics committee address [1] 308770 0
199 Ipswich Rd
Woolloongabba
Brisbane 4102
Queensland
Ethics committee country [1] 308770 0
Australia
Date submitted for ethics approval [1] 308770 0
09/11/2020
Approval date [1] 308770 0
10/03/2021
Ethics approval number [1] 308770 0
HREC/2021/QMS/67093

Summary
Brief summary
Cognitive remediation is an evidence based therapy to address the thinking problems (e.g. trouble attending, remembering or planning) associated with schizophrenia and related disorders. The exact mechanism of benefit is unclear. This pilot study explores one potential mechanism of effect and that is reward learning ( the rewards that follow learning experiences). Reward learning will be measured before the 12 week intervention and post intervention using clinical measures, pen and paper measures as well as images of the brain that reflect reward learning.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 111822 0
A/Prof Frances Dark
Address 111822 0
Princess Alexandra Hospital and Health Service Addiction and Mental health service
199 Ipswich Rd
Woolloongabba
Brisbane 4102
Queenlsand
Country 111822 0
Australia
Phone 111822 0
+61 488412054
Fax 111822 0
Email 111822 0
frances.dark@health.qld.gov.au
Contact person for public queries
Name 111823 0
A/Prof Frances Dark
Address 111823 0
Princess Alexandra Hospital and Health Service Addiction and Mental health service
199 Ipswich Rd
Woolloongabba
Brisbane 4102
Queensland
Country 111823 0
Australia
Phone 111823 0
+61 7 31762111
Fax 111823 0
Email 111823 0
frances.dark@health.qld.gov.au
Contact person for scientific queries
Name 111824 0
A/Prof Frances Dark
Address 111824 0
Princess Alexandra Hospital and Health Service Addiction and Mental health service
199 Ipswich Rd
Woolloongabba
Brisbane 4102
Queensland
Country 111824 0
Australia
Phone 111824 0
+61 7 31762111
Fax 111824 0
Email 111824 0
frances.dark@health.qld.gov.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
What supporting documents are/will be available?
Study protocol
How or where can supporting documents be obtained?
Type [1] 12099 0
Study protocol
Citation [1] 12099 0
Link [1] 12099 0
Email [1] 12099 0
frances.dark@health.qld.gov.au
Other [1] 12099 0
Summary results
No Results